Disposition of 9268 shares by Rhonda Farnum of Theravance Biopharma at 9.1 subject to Rule 16b-3

TBPH Stock  USD 9.47  0.14  1.46%   
Under 62% of Theravance Biopharma's investor base is looking to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are alarmed at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.
  
Filed transaction by Theravance Biopharma Officer: Svp, Comm & Medical Affairs. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 9268 ordinary shares at 9.1 of Theravance Biopharma by Rhonda Farnum on 20th of May 2024. This event was filed by Theravance Biopharma with SEC on 2024-05-20. Statement of changes in beneficial ownership - SEC Form 4

Theravance Biopharma Fundamental Analysis

We analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Theravance Biopharma is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Theravance Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theravance Biopharma stock to make a market-neutral strategy. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with similar companies.

Peers

Theravance Biopharma Related Equities

SNSESensei Biotherapeutics   8.33   
0%
100.0%
TILInstil Bio   5.61   
0%
67.0%
NUVBNuvation Bio   3.70   
0%
44.0%
CTMXCytomX Therapeutics   2.30   
0%
27.0%
ASMBAssembly Biosciences   2.17   
0%
26.0%
CNTBConnect Biopharma   1.01   
0%
12.0%
ACHLAchilles Therapeutics   0.93   
11.0%
0%
OVIDOvid Therapeutics   0.94   
11.0%
0%
NXTCNextCure   7.75   
93.0%
0%

Complementary Tools for Theravance Stock analysis

When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal